INTRODUCTION {#s1}
============

Pulmonary artery hypertension (PAH) is a debilitating condition, resulting in dyspnea and fatigue, impaired exercise capacity, and reduced survival \[[@R1]\]. When PAH develops, right ventricular (RV) and right atrial pressure (RAP) increased progressively, the fluid reabsorption of pericardial fluid via the venous or lymphatic channels draining into the right atrium is damaged, \[[@R2]--[@R6]\] leading to pericardial effusion (PE). The prevalence of PE varies from 21% to 29%, and higher in patients with connective tissue disease (CTD) \[[@R4], [@R6]\]. Pericardial fluid accumulation masks the echocardiographic findings of cardiac tamponade \[[@R6]\] and impairs the ventricular diastolic filling, which carries an additional risk to patients with PAH, \[[@R4], [@R6]\] particularly in PAH due to CTD \[[@R7]\]. As a result, PE in PAH is an indicator of right heart failure and poor prognosis.

Our group recently, reported the actual experimental \[[@R8]\] and short-term clinical results of pulmonary artery denervation (PADN) via significant reductions in pulmonary arterial pressure (PAP) and PE size, and improvement of 6MWD at 3-month follow-up in patients with idiopathic PAH who were unresponsive to medication \[[@R9]\]. We also found that the presence of PE was associated with less reduction of PAP \[[@R9]\]. However, the correlation of PE with outcomes after PADN remained to be unclear. Accordingly, the present study aimed to analyze the dynamic change of PE and its predictive value for clinical outcomes in consecutive patients with idiopathic or secondary PAH or secondary PH from left ventricular dysfunction \[LVD\] who underwent PADN procedure.

RESULTS {#s2}
=======

Patient population {#s2_1}
------------------

A total of 70 patients with qualifying PAH/PH were screened for this study. Four patients were excluded: 2 patients could not lie flat for 20 minutes, 1 died on the ward after consent while waiting for the procedure, and 1 died from temporary pacing catheter-induced RV perforation before the PADN procedure. The study population thus consisted of 66 patients for whom a PADN procedure was attempted: 21 idiopathic PAHs; 19 PHs due to LVD (16 due to prior myocardial infarction and 3 dilated cardiomyopathy); 10 CTDs (6 with systemic lupus erythematosus, 2 with mixed connective tissue disease and 2 with primary Sjogren\'s syndrome); 9 CTEs; and CHDSR in 8 patients (5 patients with atrial septal defect and 3 patients with patent ductus arteriosus which were repaired surgically). Finally, there were 39 patients in WHO Group I, 19 in Group II and 9 in Group IV according to WHO classification.

Baseline clinical characteristics {#s2_2}
---------------------------------

Compared to patients without PE, those with PE had more CTD (24.3% vs. 3.4%, *p* = 0.038, Table [1](#T1){ref-type="table"}). Increased heart rate and WHO functional class 3--4, presentation of syncope, and decrease of 6MWD demonstrated a stepwise fashion across increasing baseline PE amount. Particularly, more prostacyclin analogues were used in overall patients (68.2%) based on non-PAH expert.

###### Baseline clinical variables in all patients

                                          Overall(*n* = 66)   No effusion(*n* = 29)   Effusion\< 1 cm(*n* = 20)   Effusion≥ 1 cm(*n* = 17)   *P* valuetrends
  --------------------------------------- ------------------- ----------------------- --------------------------- -------------------------- -----------------
  **Age**, yr                             51.7 ± 15.7         50.3 ± 16.9             56.7 ± 12.3                 48.3 ± 16.7                0.674
  **Female**, n (%)                       39(59.1)            19(65.5)                12(60.0)                    8(47.1)                    0.451
  **Height**, cm                          163.8 ± 7.9         162.9 ± 7.9             162.8 ± 8.5                 166.6 ± 7.1                0.240
  **Weight**, kg                          60.6 ± 10.9         60.9 ± 10.4             58.6 ± 10.3                 62.5 ± 12.8                0.552
  **Blood pressure**, mmHg                                                                                                                   
   Systolic                               125.6 ± 15.7        125.4 ± 13.6            126.7 ± 18.2                124.8 ± 16.7               0.933
   Diastolic                              81.3 ± 12.1         79.9 ± 8.6              80.5 ± 12.9                 84.4 ± 15.9                0.463
  **Heart rate**, bpm                     77.7 ± 13.7         73.5 ± 12.5             78.5 ± 12.8                 83.9 ± 15.0                0.041
  **NT-pro BNP**, pg/ml                   2206 ± 2257         1949 ± 3194             1751 ± 1838                 3237 ± 3219                0.237
  **Borg Index**, scores                  2.43 ± 1.23         2.43 ± 1.32             2.35 ± 1.26                 2.53 ± 1.11                0.910
   Class stratification, n (%)                                                                                                               0.531
   ≤ Class 3                              53(80.3)            24(82.8)                15(75.0)                    14(82.4)                   
   Class 4--5                             13(19.7)            5(17.2)                 5(25.0)                     3(17.6)                    
  **WHO functional class**, points        2.68 ± 0.64         2.52 ± 0.63             2.75 ± 0.44                 2.88 ± 0.78                0.146
   Class stratification, n (%)                                                                                                               0.012
   Class 1--2                             23(34.8)            12(41.4)                5(25.0)                     6(35.3)                    
   Class 3--4                             43(65.2)            17(58.6)                15(75.0)                    11(63.7)                   
  **6-minute walk distance**, m           357.6 ± 117.9       389.3 ± 119.8           354.3 ± 118.3               307.2 ± 101.6              0.022
  **Etiologies**, n (%)                                                                                                                      
   Idiopathic PAH                         21(31.8)            9(31.0)                 3(15.0)                     9(52.9)                    0.076
   Connective tissue disease              10(15.2)            1(3.4)                  5(25.0)                     4(23.5)                    0.038
   CHD surgical repair                    8(12.1)             5(17.2)                 2(10.0)                     1(5.9)                     0.492
   Left heart dysfunction                 19(28.8)            10(34.5)                6(30.0)                     3(17.6)                    0.472
   CTEPH                                  9(13.6)             3(10.3)                 5(25.0)                     1(5.9)                     0.189
  **Time to diagnosis of PAH**, yr        3.80 ± 0.65         4.31 ± 1.14             3.42 ± 1.28                 3.38 ± 0.67                0.791
  **Presentation at enrollment**, n (%)                                                                                                      
   Syncope                                14(21.2)            1(3.4)                  4(20.0)                     9(52.9)                    \< 0.001
   Fatigue                                62(93.9)            27(93.1)                18(90.0)                    16(94.1)                   0.880
   Chest pain                             14(21.2)            6(20.7)                 4(23.5)                     4(23.5)                    0.892
   Dyspnea                                65(98.5)            28(96.6)                20(100.0)                   17(100.0)                  0.877
  **Medication before PADN**, n (%)                                                                                                          
   Calcium channel antagonist             7(10.6)             4(13.8)                 2(10.0)                     1(5.9)                     0.698
   ERA                                    14(21.2)            6(20.7)                 4(20.0)                     4(23.5)                    0.860
   Prostacyclin                           45(68.2)            20(69.0)                11(55.0)                    14(82.4)                   0.274
   5′-PDE                                 4(6.1)              1(3.4)                  1(5.0)                      2(11.8)                    0.337
   Diuretics                              48(72.7)            19(65.5)                15(75.0)                    14(82.4)                   0.174
   Digoxin                                22(33.3)            10(34.5)                6(30.0)                     6(35.3)                    0.925

NT, N-terminal; BNP, brain natriuretic peptide; PAH, pulmonary arterial hypertension; CHD, congenital heart disease; CTEPH, chronic thromboembolitic pulmonary hypertension; ERA, endothelin receptor antagonist; 5′-PDE, phosphodiesterase type-5 inhibitors

Measurements by echocardiograph and right heart catheterization {#s2_3}
---------------------------------------------------------------

Moderate to severe PE was associated with higher PAP, RAP, RVP, PVR, Tei index, and lower CO (Table [2](#T2){ref-type="table"}), compared to no or mild PE. Notably, RA area increased in a stepwise fashion across increasing the amount of PE (*p* \< 0.001, Table [2](#T2){ref-type="table"}).

###### Measurements by cardiac echo and right heart catheterization in all patients

                                       Overall(*n* = 66)   No effusion(*n* = 29)   Effusion\< 1 cm(*n* = 20)   Effusion≥ 1 cm(*n* = 17)   *P* valuetrends
  ------------------------------------ ------------------- ----------------------- --------------------------- -------------------------- -----------------
  **Echocardiographic measurements**                                                                                                      
    LADs, mm                           41.9 ± 8.9          40.3 ± 7.6              44.9 ± 9.2                  40.9 ± 10.2                0.188
    LVDd, mm                           44.6 ± 12.2         46.1 ± 12.4             44.6 ± 10.1                 42.0 ± 14.2                0.543
    LVDs, mm                           29.9 ± 12.5         31.4 ± 13.3             29.7 ± 9.1                  27.5 ± 14.7                0.606
    LVEF, %                            62.5 ± 12.3         61.5 ± 14.6             62.2 ± 8.2                  64.8 ± 12.5                0.672
    Systolic PA pressure, mmHg         92.8 ± 30.8         85.5 ± 34.8             88.7 ± 22.3                 110.0 ± 26.7               0.023
    Mean PA pressure, mmHg             42.3 ± 15.9         45.3 ± 16.4             39.1 ± 12.9                 40.8 ± 13.2                0.531
  Systolic RV pressure, mmHg           91.8 ± 30.5         83.9 ± 33.4             87.7 ± 22.8                 110.0 ± 26.6               0.013
    Mean RA pressure, mmHg             12.0 ± 6.4          10.3 ± 3.5              11.9 ± 3.6                  15.0 ± 5.4                 0.018
    RA diameter, mm                                                                                                                       
   Long-axis                           58.6 ± 11.2         53.2 ± 9.7              61.1 ± 11.6                 65.1 ± 9.2                 0.001
   Short-axis                          49.3 ± 10.6         44.1 ± 7.9              51.6 ± 9.8                  55.6 ± 11.6                0.001
    RA area, cm^2^                     23.4 ± 9.1          18.8 ± 6.0              25.4 ± 9.2                  29.0 ± 9.5                 \< 0.001
    Pericardial fluid, mm              2.75 ± 3.39         0                       5.49 ± 1.29                 11.76 ± 1.08               \< 0.001
    Tei                                0.63 ± 0.15         0.59 ± 0.16             0.62 ± 0.15                 0.71 ± 0.14                0.039
  **Measurements by RHC**                                                                                                                 
    Systolic PA pressure, mmHg         87.9 ± 29.8         85.4 ± 35.4             88.5 ± 17.9                 103.5 ± 25.2               0.029
    Mean PA pressure, mmHg             53.1 ± 19.1         51.7 ± 22.4             57.8 ± 11.6                 61.8 ± 17.7                0.039
    PCWP, mmHg                         14.8 ± 11.5         15.6 ± 12.7             13.1 ± 9.0                  15.4 ± 12.5                0.736
    Mean RA pressure, mmHg             12.6 ± 7.2          11.5 ± 7.9              11.8 ± 6.2                  16.5 ± 5.8                 0.031
    Systolic RV pressure, mmHg         86.3 ± 29.0         82.8 ± 35.3             84.5 ± 17.6                 97.8 ± 26.1                0.033
    PVR, Wood Units                    13.8 ± 8.6          12.8 ± 6.8              13.3 ± 7.5                  18.6 ± 12.4                0.036
    Cardiac output, L/min              3.26 ± 1.25         3.26 ± 1.32             3.21 ± 1.15                 2.66 ± 1.23                0.042

LADs, left atrial diameter at end-systole; LVDd, left ventricular diameter at end-diastole; LVDs, left ventricular diameter at end-systole; LVEF, left ventricular eject fraction; PA, pulmonary artery; RV, right ventricular; RA, right atrial; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vessel resistance.

As shown in Table [3](#T3){ref-type="table"}, a greater mean absolute reduction of mPAP and sPAP just post-PADN was achieved in patients without PE (−12.1 mmHg and −12.3 mmHg ), when compared to patients with PE ≥ 1 cm (−4.0 mmHg and −6.3 mmHg) and patients with PE \< 1 cm (−4.3 mmHg and −8.8 mmHg, *p* = 0.017 and *p* = 0.023, respectively). After 24 h post-PADN, the reduction of sPAP and mPAP was comparable between three groups, a finding in consistent with the dynamic change of pericardial fluid amount (Figure [1](#F1){ref-type="fig"}): less reduction just post-PADN, almost 50% reduction at 24 h after PADN treatment (*p* \< 0.001). Since then, gradual absorption of PE over the time was associated with greater reduction of sPAP and mPAP in patients with PE (Table [3](#T3){ref-type="table"}). The reduction of PE in the Group I seemed to be great but non-significant to that in Group II and Group IV (Figure [1](#F1){ref-type="fig"}), leading to similar improvement of hemodynamic between groups (data not showed here).

###### Dynamic change of hemodynamic parameters measured by right catheterization

                                  Overall (*n* = 66)   No effusion (*n* = 29)   Effusion \< 1 cm (*n* = 20)   Effusion ≥ 1 cm (*n* = 17)   *P* value trends
  ------------------------------- -------------------- ------------------------ ----------------------------- ---------------------------- ------------------
  **Reduction of systolic PAP**                                                                                                            
  **Post-PADN**                                                                                                                            
   Absolute value, mmHg           −8 ± 10              −12.3 ± 13.6             −8.8 ± 11.4                   −6.3 ± 8.0                   0.023
   Percentage, %                  −11 ± 12             −14.8 ± 13.5             −10.8 ± 10.2                  −6.2 ± 7.5                   0.036
  **24 h**                                                                                                                                 
   Absolute value, mmHg           −9.6 ± 13            −12.4 ± 18.2             −10.2 ± 12.7                  −8.7 ± 11.4                  0.070
   Percentage, %                  −11 ± 16             −13.5 ± 15.8             −11.4 ± 18.7                  −10.9 ± 13.5                 0.993
  **End of follow-up**                                                                                                                     
   Absolute value, mmHg           −17.9 ± 14.5         −13.5 ± 9.1              −18.8 ± 16.1                  −21.3 ± 16.2                 0.242
   Percentage, %                  −20.4 ± 13.9         −14.6 ± 16.3             −20.1 ± 21.2\*                −22.8 ± 23.1\*               0.563
  **Reduction of mean PAP**                                                                                                                
  **Post-PADN**                                                                                                                            
   Absolute value, mmHg           −5 ± 11              −12.1 ± 12.5             −4.3 ± 5.7                    −4.0 ± 5.1                   0.017
   Percentage, %                  −12 ± 19             −22.7 ± 20.2             −7.7 ± 12.0                   −6.5 ± 18.8                  0.006
  **24 h**                                                                                                                                 
   Absolute value, mmHg           −6.6 ± 10            −9.3 ± 13.1              −6.8 ± 7.9                    −4.8 ± 6.4                   0.052
   Percentage, %                  −13 ± 18             −19.5 ± 21.6             −12.5 ± 12.4                  −7.7 ± 17.3                  0.048
  **End of follow-up**                                                                                                                     
   Absolute value, mmHg           −10.5 ± 8.5          −9.4 ± 8.8               −11.6 ± 8.7                   −11.1 ± 8.1                  0.657
   Percentage, %                  −19.3 ± 20.6         −19.7 ± 14.4             −20.3 ± 21.6\*                −19.1 ± 20.4\*               0.218

\**p* \< 0.01, compared to the percentage of reduction post-PADN.

PAP, pulmonary arterial pressure; PADN, pulmonary artery denervation.

![Dynamic change of pericardial effusion (PE)\
PADN was associated with significant reduction of PE in three groups classified by WHO definition.](oncotarget-08-54106-g001){#F1}

Of 37 patients with PE, complete disappearance of PE at the end of follow-up was seen in 4 patients; PE increased to near baseline level in 3 patients who had significantly reduced PE at 3 month after PADN, these 3 patients died thereafter. Of 29 patients without PE, newly appearance of PE was seen in 1 patient.

Morbidity and mortality {#s2_4}
-----------------------

Median (interquartile range) follow-up was 376(307--999) days. As shown in Table [4](#T4){ref-type="table"} and Figure [2](#F2){ref-type="fig"}, PAH-related adverse events occurred in 10 (15.2%) patients during follow-up, including 1 patient without PE, 3 mild PE and 6 moderate/severe PE (3.3% vs. 15.0% vs. 35.3%, *p* = 0.008, Figure [2A](#F2){ref-type="fig"}). Most events occurred within one-year. There was no procedure-related complication.

###### Clinical outcomes during follow-up

                                      Overall (*n* = 66)   No effusion (*n* = 29)   Effusion \< 1 cm (*n* = 20)   Effusion ≥ 1 cm (*n* = 17)   *P* value trends
  ----------------------------------- -------------------- ------------------------ ----------------------------- ---------------------------- ------------------
  **Follow-up** (d, median \[IQR\])   376 (307−999)        374 (309−980)            380 (307−999)                 377 (310−911)                0.908
  **PAH-related events**, *n* (%)     10 (15.2)            1 (3.4)                  3 (15.0)                      6 (35.3)                     0.015
  Death                               6 (9.1)              0                        2 (10.0)                      4 (23.3)                     0.044
  Atrial septostomy                   0                    0                        0                             0                            NS
  In list for lung transplant         2 (3.0)              0                        0                             2 (11.8)                     0.051
  Needing IV or SQ drugs              6 (9.1)              0                        1 (5.0)                       5 (29.4)                     0.003
  Worsening of PAH                    8 (12.1)             1 (3.4)                  2 (10.0)                      5 (29.4)                     0.032
   6MWD decline by \> 15%             8 (12.1)             1 (3.4))                 2 (10.0)                      5 (29.4)                     0.032
   Worsening of symptoms^\#^          8 (12.1)             1 (3.4)                  2 (10.0)                      5 (29.4)                     0.032
   Additional treatments              14 (21.2)            3 (10.3)                 4 (20.0)                      7 (41.2)                     0.047
  **All-cause death**, *n*(%)         8 (12.1)             1 (3.4)                  2 (10.0)                      5 (29.4)                     0.032
  **Rehospitalization**, *n* (%)      11 (16.7)            2 (6.8)                  3 (15.0)                      6 (35.3)                     0.037

IQR, interquartile range; PAH, pulmonary arterial hypertension; IV, intravenous; SQ, subcutaneous; 6MWD, 6-minute walk distance.

^\#^defined as a change from baseline to a higher WHO functional class (or no change in patients who were in WHO functional class IV at baseline) plus the appearance or worsening signs of right heart failure not response to oral diuretics therapy.

![Kaplan-Meier survival analysis\
Patients with moderate and severe pericardial effusion had lower PAH-related event-free survival rate (**A**) and all-cause-free survival rate (**B**) and worsening of PAH (**C**).](oncotarget-08-54106-g002){#F2}

All-cause mortality occurred in 8 patients (12.1%) during follow-up, with a significant different rate in those without PE (3.4%), with mild PE (10%) and with moderate to severe PE (29.4%, *p* = 0.032, Figure [2B](#F2){ref-type="fig"}). The rate of PAH-related event was comparable between patients with Group I, Group II and Group IV PAH (Data not showed here). Similarly, patients with PE had increased rate of the worsening of PAH (Figure [2C](#F2){ref-type="fig"}).

Univariate analysis {#s2_5}
-------------------

As shown in Table [5](#T5){ref-type="table"}, univariate analysis showed that patients who had PAH-related event or all-cause death had increased PAP and systolic RVP, and RAP estimated by echo, more pericardial fluid, and decreased 6MWD.

###### Univariate analysis of the associations with PAH-related event and all-cause death

                               For PAH-related event           For All-cause death   
  ---------------------------- ----------------------- ------- --------------------- -------
  **Variables by RHC**                                                               
   Systolic PAP                −40.992∽−1.191          0.038   −46.248∽−2.701        0.021
   Mean PAP                    −29.241∽−4.261          0.009   −32.629∽−5.281        0.007
   Mean RAP                    −9.590∽−0.098           0.055   −9.967∽0.746          0.090
    Systolic RV pressure       −40.084∽−1.348          0.036   −44.218∽−1.689        0.035
  **Variables by echo**                                                              
   Systolic RV pressure        −46.079∽−6.042          0.012   −52.111∽−8.398        0.007
   Systolic PAP                −43.748∽−2.787          0.027   −49.542∽−4.777        0.018
   Mean RA pressure            −8.912∽−0.445           0.031   −10.137∽−0.889        0.020
   Pericardial effusion        −7.198∽−1.456           0.004   −7.453∽−1.057         0.001
  **6-minute walk distance**   16.154∽172.324          0.019   3.688∽177.097         0.041

HRC, right heart catheterization; PAP, pulmonary arterial hypertension; RAP, right atrial pressure; RV, right ventricular

DISCUSSION {#s3}
==========

The current study for the first time reports the correlation of baseline pericardial effusion with clinical outcome after PADN in patients with different etiologies of PAH. The major findings are: (1) the presence of PE is the mark of the severity of PAH; (2) PADN led to significant reduction of PE, with subsequent less PAH-related event, all-cause death and worsening of PAH.

Mechanism of PE in PAH {#s3_1}
----------------------

The echocardiographic factors that adversely affect prognosis in PAH are RV dysfunction and the presence of PE \[[@R2], [@R3]\]. When PAH develops, a higher RAP that limits the drainage of pericardial veins into the RA. On the other hand, inflammatory conditions, such as systemic lupus erythematosus and scleroderma, can independently affect the pericardium and lead to PE, \[[@R4], [@R6]\] in line with our finding that more patients with PE had CTD. Previous studies \[[@R2]--[@R6]\] have clearly showed that the presence or persistence of PE in PAH despite vasoactive therapy predicted worse outcomes, a result further supported by our finding that patients with PE had increased worse clinical events after PADN. Given the prognostic value of PE, the absence or resolution of PE with novel therapy should have suggested better prognosis \[[@R6]\].

Sympathetic nerves, PE and PADN {#s3_2}
-------------------------------

The causality of PE and sympathetic nervous activity in the setting of PAH remains to be unknown. In general, the over activation of sympathetic nerves was evidenced by increased circulating catecholamine levels, \[[@R10], [@R11]\] abnormally high muscle sympathetic nerve activity (MSNA) \[[@R12], [@R13]\] and impaired heart rate variability \[[@R14]\]. PA is innervated by complex network of sympathetic nerves \[[@R15], [@R16]\] but its distribution in human body is under studied. Our unpublished experimental study showed that main trunk of sympathetic nerves was close to and paralleled to main stem of PA, an anatomic feature favors the performance of percutaneous intraluminal intervention \[[@R9]\].

Our finding that \> 10% reduction of PAP on-treatment could be explained by the inhibitory effect of PADN on vessel constriction induced by overactivated sympathetic nerves, as PADN-induced sympathetic nerves injury could abolish the increase of PAP in an acute PH model resulted from balloon-distention.8 Furthermore, the reduction of PAP in a stepwise fashion across the crossing the baseline amount of PE implied the complicated interplay between PE and PAP. Taking together, overactivated sympathetic nerves activity played a critical role in maintaining the vicious circle involving RV failure, increased PAP and RAP, and accumulation of pericardial fluid.

Risk models for patients with PAH treated by medications have been established \[[@R7], [@R17]\]. The present univariate analysis showed that PAP, estimated RAP by echo, PE, and 6MWD correlated with PAH-related event and mortality after PADN, in line with previous studies using medication \[[@R18]--[@R21]\]. This could be at least partially explained by the greater reduction of PAP, with resultant resolution of PE, achieved by PADN procedure.

Limitations {#s3_3}
-----------

Small patient size was the first limitation. However, our results provided stronger evidences showing the prognostic value of PE for outcomes after PADN. Next, our results came from a single-center, and bias could be excluded. As an emerging treatment for PAH, even though PADN was only performed in several global tertiary centers, our data was recorded from real patients underwent PADN procedures. Finally, we did not analyze the correlation of PE with already established risk model. However, our data clearly showed that size of PE was the only predictor of clinical outcome after PADN.

MATERIALS AND METHODS {#s4}
=====================

Patient population {#s4_1}
------------------

Between March 2012 and July 2014, patients with either idiopathic PAH or PH arising from chronic thromboemboli (CTE) after surgery, CTD, from congenital heart disease after surgical repair (CHDSR), or secondary from left ventricular dysfunction (LVD) were considered for possible treatment with PADN, if their resting mean PAP (mPAP) ≥ 25 mmHg (for all patients) and pulmonary vascular resistance (PVR) ≥ 3 Wood Units (for PH secondary from LVD) measured by right heart catheterization (RHC). Exclusion criteria included active infection, cancer, toxin- or anorexia-induced PH, portal hypertension, CTEPH without surgical treatment, intolerable to PADN procedure and inability to provide consent. The study was approved by the Institutional Review Board and Ethics Committee of the Nanjing First Hospital (Nanjing, China), and all patients provided written inform consent.

RHC measurements {#s4_2}
----------------

Resting RAP, RV pressure, PAP, pulmonary artery occlusion pressure (PAOP) or left ventricular end-diastolic pressure, \[[@R1], [@R22], [@R23]\] and cardiac output (CO) were obtained with a 7F flow-directed Swan-Ganz catheter. PVR (\[mean PAP-PAOP\]/CO) was then derived. All measurements were taken at end-expiration.

PADN procedure {#s4_3}
--------------

PADN was performed using a dedicated 7-F temperature-sensing ablation catheter. The details of the device and PADN procedure have been previously described \[[@R8], [@R9]\]. Briefly, PADN was performed only in the peri-conjunctional area between the distal main trunk and ostial left branch.

Peri-procedural medication {#s4_4}
--------------------------

Following the procedure, oral warfarin was prescribed and adjusted to an International Normalized Ratio (INR) of 1.5--2.5 for all patients. Aspirin (100 mg/d) and clopidogrel (75 mg/d) were indefinitely prescribed in the presence of contraindications for warfarin.

Assessment of functional capacity {#s4_5}
---------------------------------

Functional capacity was determined using a standard 6-minute walk distance (6MWD), \[[@R1]\] Borg scale, \[[@R24]\] and the World Health Organization (WHO) functional classification \[[@R1]\] by a physician blinded to the study design.

Echocardiographic measurements {#s4_6}
------------------------------

Transthoracic echocardiography was performed and analyzed at the Nanjing Medical University Echocardiographic Laboratory. Measurements were performed according to American Society of Echocardiography guidelines. \[[@R25], [@R26]\] Digital echocardiographic data that contained a minimum of 3 consecutive beats (or 5 beats in cases of atrial fibrillation) were acquired and stored. Systolic RVP was set equal to systolic PAP (sPAP) in the absence of pulmonary stenosis. sPAP was calculated as the sum of RAP and the RV to RA pressure gradient during systole. RAP was estimated based on the echocardiographic features of the inferior vena cava and assigned a standard value. The RV to RA pressure gradient was calculated as 4 vt^2^ using the modified Bernoulli equation. The mPAP was estimated according to the velocity of the pulmonary regurgitation jet in m/s. The tricuspid excursion index (Tei) was defined as (A--B)/B, where A was the time interval between the end and the onset of tricuspid annular diastolic velocity, and B was the duration of tricuspid annular systolic velocity (or the RV ejection time) \[[@R26]\]. RA area was defined as πab, where a was the long semi-radius of RA, and b was the short semi-radius. \[[@R25], [@R26]\] Pericardial effusion severity was characterized as trace to small if the pericardial space separated by \< 1 cm in diastole in any plane. Moderate or greater effusion was defined as pericardial space separation of ≥ 1 cm during diastole described previously \[[@R2]\].

Definitions {#s4_7}
-----------

PAH-related clinical events, defined as those caused by worsening of PAH, initiation of treatment with intravenous or subcutaneous prostanoids, lung transplantation, atrial septostomy, or all-cause death. Worsening of PAH was defined as the occurrence of all three of the following: a decrease in 6MWD of ≥ 15% from baseline, confirmed by a second 6MWD performed on a different day within 14 days; worsening symptoms of PAH; and the need for additional treatment for PAH. Worsening symptoms of PAH was defined as a change from baseline to a higher WHO functional class (or no change in patients who were in WHO functional class IV at baseline) plus the appearance or worsening signs of right heart failure not responsive to oral diuretic therapy. An independent clinical event committee adjudicated all deaths and reported events as to their relationship to PAH.

Statistical analysis {#s4_8}
--------------------

Continuous variables were expressed as mean ± SD. Normality was examined using Kolmogorov--Smirnov and Shapiro--Wilk tests. Differences in continuous variables between groups were analyzed using *t* test or Wilcoxon\'s rank sum tests, as appropriate. Categorical variables were compared using Fisher\'s exact test. Event-free survival was estimated using the Kaplan-Meier method and differences between groups compared with the log-rank test. Univariate analysis was performed to determine if pericardial fluid amount was the independent factor of clinical events. Statistical significance was defined as a two-sided *P* value \< 0.05. All analyses were performed using SPSS 16.0 (SPSS Institute Inc., Chicago, Ill., USA)

CONCLUSIONS {#s5}
===========

The present study has demonstrated PE serves as a hallmark of severe progressive PAH. PADN results in significant absorption of PE with subsequent improvement of clinical outcomes. Multicenter randomized trials are warranted to determine the utility of PADN in high-risk patients with PAH.
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